BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) investors concerning the Company's possible violations of federal securities laws.
Investors interested in stocks from the Medical Services sector have probably already heard of PACS Group, Inc. (PACS) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON MEDPACE HOLDINGS, INC. (MEDP), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On February 9, 2026, Medpace released its fourth quarter 2025 f.
In the closing of the recent trading day, Medpace (MEDP) stood at $508.52, denoting a +2.52% move from the preceding trading day.
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), have until June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v.
NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
SAN DIEGO--(BUSINESS WIRE)---- $MEDP #Health--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Medpace Holdings Inc. (NASDAQ: MEDP) securities between April 22, 2025 and February 9, 2026. Medpace is a clinical contract research organization (CRO) focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. For more information, submit a form, ema.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026. Medpace describes itself as a “clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.”For more information, submit a fo.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options
